Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04073966 · ClinicalTrials.gov registry record
MRI Biomarkers for Radiation-Induced Neurocognitive Decline Following SRS of Newly Diagnosed Brain Mets
A clinical trial of Brain Metastases and Radiation Exposure, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Recruiting
- Registry status
- 15
- Enrollment target
- 1
- Study location
NCT04073966 is a study of Brain Metastases and Radiation Exposure that is actively recruiting participants, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 15 participants, below the 213-participant average among 67 other Brain Metastases trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04073966, a study of Brain Metastases and Radiation Exposure, is actively recruiting participants, sponsored by UNC Lineberger Comprehensive Cancer Center.
- RECRUITING
- Registry status
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
Brain metastases are a source of much morbidity and mortality in adults with primary solid malignant tumors. With improvements in systemic therapy that prolong survival but have limited central nervous system penetration, patients with brain metastases are at increasing risk of developing and experiencing long-term side effects from treatment of brain metastases. The overarching goal of this study is to better understand the determinants of RT-associated changes in white and gray matter function and associated neurocognitive decline.
Conditions Studied
Study Locations (1)
North Carolina
- University of North Carolina at Chapel Hill, Department of Radiation Oncology - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-12-04 |
| Est. Completion | 2026-09-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04073966
The ClinicalTrials.gov registry entry for NCT04073966 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 213-participant average among 67 other Brain Metastases trials with a reported enrollment target (93% lower). The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Brain Metastases appearing as the primary indexed condition, and to 0 interventions.
NCT04073966 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT04073966 about?
NCT04073966 is a clinical study titled "MRI Biomarkers for Radiation-Induced Neurocognitive Decline Following SRS of Newly Diagnosed Brain Mets". Brain metastases are a source of much morbidity and mortality in adults with primary solid malignant tumors. With improvements in systemic therapy that prolong survival but have limited central nervous system penetration, patients with brain metastases are at increasing risk of developing and experi...
What is the current status of trial NCT04073966?
This trial is currently recruiting. The enrollment target is 15 participants. The study started on 2019-12-04. Estimated completion is 2026-09-15.
What conditions does trial NCT04073966 study?
This clinical trial studies the following conditions: Brain Metastases, Radiation Exposure, Neurocognitive Deficit, White Matter Alterations.
Who is sponsoring clinical trial NCT04073966?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04073966 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
RECRUITING · Phase 1
-
Trial of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases
RECRUITING · NA
-
Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer
RECRUITING · Phase 4
-
7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI)
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.